Contra-indicated in patients with a history of stroke, transient ischemic attack, or intracranial hemorrhage, or with active pathological bleeding.
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Zontivity (Merck)
- INDICATIONS: Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease
- CLASS: Protease-activated receptor-1 (PAR-1) antagonist
- HALF-LIFE: 3–4 days
- FDA APPROVAL DATE: 05/08/2014
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Boceprevir, Carbamazepine, Clarithromycin, Conivaptan, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Strong CYP3A inhibitors or inducers, Telaprevir, Telithromycin
BLEEDING RISK
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
